Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
2.320
-0.080 (-3.33%)
Mar 31, 2025, 3:45 PM EDT - Market open
Traws Pharma Employees
As of December 31, 2023, Traws Pharma had 18 total employees, including 17 full-time and 1 part-time employees. The number of employees increased by 1 or 5.88% compared to the previous year.
Employees
18
Change (1Y)
1
Growth (1Y)
5.88%
Revenue / Employee
$12,556
Profits / Employee
-$7,821,389
Market Cap
8.47M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TRAW News
- 2 days ago - Traws Pharma Announces Management Updates - GlobeNewsWire
- 5 days ago - Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET - GlobeNewsWire
- 6 days ago - Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR - GlobeNewsWire
- 10 days ago - Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR - GlobeNewsWire
- 4 weeks ago - Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil - GlobeNewsWire
- 4 weeks ago - Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule - GlobeNewsWire
- 2 months ago - Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu - PRNewsWire
- 2 months ago - Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program - PRNewsWire